Aim: Several lines of evidence implicate glutamatergic dysfunction in the pathophysiology of obsessive-compulsive disorder (OCD), presenting this neurotransmitter as a target for the development of novel pharmacotherapy. The objective of this study was to assess the efficacy of minocycline as an augmentative agent to fluvoxamine in the treatment of patients with OCD.
on the development of novel agents in the pharmacotherapy of OCD. [11] [12] [13] [14] [15] Several lines of evidence suggest that OCD can be caused by glutamatergic dysfunction in orbitofrontal/basal ganglia brain circuits. 16, 17 Neuroimaging studies demonstrated reduction of glutamatergic neurotransmission in the anterior cingulate cortex of OCD patients. 18 Glutamate in the cerebrospinal fluid (CSF) of OCD patients is increased and this provides evidence in support of the neurobiological models of OCD. 19 In previous studies, 30-54% of OCD patients responded to glutamate modulators as an augmentation agent to SRI. [20] [21] [22] [23] [24] Minocycline is the most widely prescribed antibiotic for chronic acne due to lower antibiotic resistance compared to other tetracyclines and antimicrobials. 25 Minocycline passes the blood-brain barrier. Prior trials have shown neuroprotective effects of minocycline in amyotrophic lateral sclerosis and Parkinson's disease. 26, 27 In animal studies, minocycline has been reported to significantly reduce 3,4-methylenedioxymethamphetamineinduced neurotoxicity of 5-hydroxytryptamine and dopamine systems in the cerebral cortex and hippocampus and to promote neurogenesis. 28 Minocycline has a regulatory effect on pro-inflammatory agents, including nitric oxide, tumor necrosis factor-α, and interleukin-1β. 29 Animal studies have shown that minocyclines decrease glutamate-induced neurotoxicity. 30 Minocycline has therapeutic effects on neurodegenerative diseases and this might be achieved through the blockade of glutamate-mediated excitotoxicity. 31 Moreover, this antibiotic is known for its antioxidant and anti-inflammatory characteristics, which could further explain its neuroprotective effects. 32 Previously, we have demonstrated the beneficial role of minocycline in improving symptoms of schizophrenia, depressive and autistic symptoms. [33] [34] [35] The present study was conducted to investigate the efficacy and safety of minocycline as an augmentative agent to fluvoxamine, an SRI strongly supported by OCD randomized trials in treatment of moderate-to-severe OCD patients.
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METHODS
Trial setting and design
A 10-week, single-center, randomized, double-blind, placebo-controlled, parallel-group trial was performed in the outpatient clinic of Roozbeh Psychiatric Hospital (teaching hospital of Tehran University of Medical Sciences, Tehran, Iran) from March 2015 to January 2016. The trial was approved by the ethics committee of Tehran University of Medical Science (Grant No.: 27224) and conducted according to the Declaration of Helsinki and subsequent revisions. Written informed consent was obtained from all subjects before participation. Patients were informed that their participation was voluntary and that they could withdraw from the trial at any time with no negative effect on their treatment. The trial was registered at the Iranian Registry of Clinical Trials (www.irct.ir; registration number: IRCT201501031556N70).
Participants
Patients, aged 18-50 years, with a clinical diagnosis of OCD according to the DSM-IV-TR, were screened for the study. Those with a diagnosis of moderateto-severe OCD defined by a Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score of ≥21 were included. 38, 39 Patients were excluded from the study if they had any other comorbid DSM-IV axis I disorders, serious medical or neurological condition, substance dependence (other than caffeine or nicotine), mental retardation (based on clinical judgment), pregnancy, breast-feeding, or any contraindication for the use of minocycline or fluvoxamine, hepatic or renal disease, seizure, lupus, neutropenia, anemia, thrombocytopenia, head trauma, history of previous psychosurgery for OCD, or any hypersensitivity to the tetracycline antibiotics group. During the course of the trial, patients were not allowed to participate in psychotherapeutic sessions. Patients were also excluded if they had received any psychotropic drugs in the previous 6 weeks.
Interventions
Eligible participants were randomized to receive either minocycline (Hexal, 100-mg tablet), 100 mg twice per day, or placebo for 10 weeks. All participants, regardless of group assignment, also received fluvoxamine (Sobhan, 50-mg and 100-mg tablets), 100 mg/day for 28 days, followed by 200 mg/day for the rest of the trial.
Outcome
Y-BOCS was used to evaluate treatment efficacy. This is a well-validated 10-item rating scale, which is widely used to measure the severity of OCD symptoms and has also been applied in several clinical trials in Iran. [11] [12] [13] [14] Participants were rated by Y-BOCS at baseline and at weeks 4 and 10.
The main outcome measure was difference in score change of the Y-BOCS total score from the baseline to the end of the trial between the two groups. Differences in score change of the Y-BOCS Obsession and Compulsion subscales from baseline to week 10 as well as differences in score change of total and subscale scores from baseline to other time-points were assigned as secondary outcome measures. Other secondary outcome measures included differences in partial response rates (defined as ≥25% reduction in Y-BOCS score), complete response rates (≥35% reduction in Y-BOCS score) and remission rates (score ≤16) between the two groups. 40 Regarding the adverse events, participants were strongly encouraged to contact the study team about any unexpected adverse events occurring during the use of the drugs. Adverse events were recorded using a structured checklist at each visit. Participants were first asked an open-ended question about the occurrence of any adverse event. Furthermore, all patients received a phone call 1 week after treatment initiation to evaluate possible adverse effects. All participants underwent a thorough physical examination and measurement of a complete blood count (CBC), liver and kidney function test values at baseline and at each post-baseline visit.
Sample size
With the assumption of a difference of four points on Y-BOCS scores between the minocycline and the placebo groups, an SD of 5, a two-sided significance level of 0.05, and a statistical power of 95%, a sample size of 84 (each group 42) was calculated. Predicting a dropout rate of 20%, a total number of 102 participants were needed.
Randomization, allocation concealment, and blinding
A computerized random-number generator was used to allocate patients into two groups in a 1/1 ratio (blocks of 4). The assignments were concealed in sequentially numbered sealed, opaque envelopes. Minocycline and placebo capsules had similar appearance, shape, size, texture, color and odor. Random allocation was performed by an independent person who was not involved elsewhere in the trial. The patients, the psychiatrists who rated them and prescribed the medication, and the statistician were all blind to allocation.
Statistical analysis
Data analysis was carried out using SPSS 22 (SPSS, Chicago, IL, USA). Numerical variables were summarized by using mean AE SD and categorical variables were presented as number of patients and percentages. Normally distributed continuous variables were compared between the minocycline and the placebo groups using the Independent t-test. The mean difference (MD) between the minocycline group and the placebo group was reported as MD, 95% confidence interval (CI). Two-factor repeatedmeasure ANOVA was used to evaluate time × treatment interaction between the treatment groups. The Greenhouse-Geisser adjustment was performed, when Mauchly's test of sphericity indicated that the assumption of sphericity had been violated. After controlling for baseline Y-BOCS scores, ANCOVA was used to compare Y-BOCS scores between the groups at the trial end. Cohen's d effect size was calculated to quantify the treatment effect. The χ 2 or Fisher's exact tests were used to compare proportions between the two groups as appropriate. All of the above-mentioned statistical analyses were performed two-sided, and P < 0.05 was considered as significant.
RESULTS
Patients
A total of 126 patients were screened for eligibility criteria. One hundred and two patients were randomly assigned to receive either minocycline plus fluvoxamine (n = 51) or placebo plus fluvoxamine (n = 51). Eight patients discontinued the trial (four patients in each group) and a total of 94 patients (47 in each group) completed the trial (Fig. 1) . Baseline characteristics of the participants are summarized in Table 1 . At baseline, no patient suffered from an infective disease that needed antibiotic usage.
Y-BOCS total score
Y-BOCS total scores did not differ significantly between the two groups at baseline, MD (95%CI) = 0.36 (−0.90 to 1.62), t (59.86) = 0.57, P = 0.56. Significant effect for time × treatment interaction, Greenhouse-Geisser corrected: F(1.49, 137.93) = 7.1, P = 0.003 (Fig. 2) , was demonstrated by repeated-measure ANOVA. ANCOVA demonstrated significantly lower scores in the minocycline group compared to the placebo group at the end of the trial course, F(1, 91) = 7.24, P = 0.008 (Table 2) , after controlling for baseline Y-BOCS total score. At the end of the trial, significantly higher remission rate, partial and complete response rates were observed in the minocycline group compared to the placebo group (Table 3) . A significantly shorter (Fig. 3) .
Y-BOCS Obsession subscale score
At baseline, Y-BOCS Obsession subscale scores did not differ between the two groups, MD (95%CI) = 0.51 (−0.20 to 1.22), t (72.06) = 1.42, P = 0.15. General linear model repeated measure demonstrated significant effect for time × treatment interaction on Y-BOCS total score, F(1.54, 141.94) = 9.72, P < 0.001 (Fig. 4) . ANCOVA, after controlling for baseline Y-BOCS Obsession subscale score, demonstrated lower scores in the minocycline arm in comparison with the placebo arm at the end of the trial course, F(1, 91) = 9.81, P = 0.002 (Table 2 ). placebo arm at the end of the trial course, F (1, 91) = 5.04, P = 0.02 (Table 2) .
Y-BOCS Compulsion subscale score
Side-effects
Adverse events were recorded during the study. Sideeffects were mild and did not result in withdrawal.
Frequency of side-effects was not different between the two groups (Table 4) .
DISCUSSION
OCD results in impaired social and occupational function of the patients. 6 Data suggest that OCD can be caused by glutamatergic dysfunction in orbitofrontal/basal ganglia brain circuits. 16, 17 There is increasing interest in augmentative strategies because 41 Minocycline has neuroprotective effects in different neurological diseases. 42 Kuloglu et al. demonstrated a significantly higher level of malondialdehyde, a product of lipid peroxidation, and glutathione peroxidase in OCD patients compared to the control group. 43 Experimental studies have consistently provided support for a deficient glutathione oxidative protective system in the animal model of OCD, especially in the frontal cortex. 44 The beneficial effect of minocycline in OCD patients is partly due to its anti-oxidative characteristics, as oxidative stress is known to be associated with OCD. 45, 46 Several lines of evidence implicate that OCD can be caused by glutamatergic dysfunction in orbitofrontal/basal ganglia brain circuits. 47 These evidences can be categorized into three main groups: (i) the observation of changes in glutamate concentrations as assessed from CSF or by magnetic resonance spectroscopy of the caudate anterior cingulate cortex in patients with OCD; (ii) studies on animal models with impaired glutamate signaling and concurrent phenotype resembling OCD; and (iii) the finding of variations in genes involving the glutamate pathway in patients with OCD. 48 Studies have shown significantly higher glutamate concentrations on the CSF of patients with OCD compared to controls. 19, 49 Rosenberg et al. studied 11 psychotropic drug-naïve children with OCD and showed significantly higher caudate glutamate concentrations in patients in comparison with healthy controls. 50 Inhibiting glutamate release has been associated with reduction in OCD-like behavior in mice, 51, 52 and glutamate system dysregulation marked by increased glutamate has been linked to compulsive or repetitive behaviours. 53 The neuroprotective effect of minocycline against glutamate excitotoxicity, through regulation of the p38 and Akt pathways, is probably another mechanism by which minocycline improves symptoms in patients with OCD. 31 The advantages of minocycline include low cost and US Food and Drug Administration approval in adults and children >12 years. 25 It has an excellent sideeffect profile. In a long-term placebo-controlled trial, minocycline was given to Huntington's disease patients for 2 years and it was well-tolerated, with no serious adverse effects. 48 Previous studies have demonstrated the beneficial role of glutamate modulators, such as riluzole and memantine, as augmentation agents to SRI. [20] [21] [22] [23] [24] [53] [54] [55] [56] An open-label augmentation trial of memantine, as a glutamatergic agent, was conducted on 15 patients with treatmentresistant OCD. Almost half the subjects had a meaningful improvement in symptoms after 12 weeks. 21 Ghaleiha et al. reported that memantine combination therapy with fluvoxamine significantly reduced the obsessive-compulsive symptoms as quantified with the Y-BOCS. 12 The effect was evident in the total score and the scores for the Obsession and Compulsion subscales. Adding memantine to fluvoxamine in treatment of OCD also resulted in more complete response in that study. 11 In another case-control study, memantine was found to be effective as a glutamatergic-augmenting agent in severe OCD. 23 An open-label trial by Rodriguez et al. assessed the effect of minocycline on nine adult outpatients with Y-BOCS scores ≥16 despite a therapeutic SRI dose. 15 The patients were on stable doses of SRI for at least 12 weeks and other concomitant psychotropic medications for at least 4 weeks prior to the study. In their trial, all patients had failed at least one adequate trial of an antipsychotic in the augmentation of an SRI. The authors showed that minocycline augmentation of SRI pharmacotherapy may not improve OCD in all adult OCD patients, but may improve symptoms in those with early-onset OCD and those with primary hoarding. 15 The difference between the findings of Rodriguez et al. and the current trial might be due to the different types of participants between the two trials. Rodriguez et al. conducted their study on treatment-resistant patients who had failed at least one adequate trial of an antipsychotic in augmentation with an SRI, whereas the subjects of the current trial were free from any psychiatric medication 6 weeks prior to the study.
In this study, minocycline was administrated with a dosage of 100 mg twice daily with no serious adverse events. The result showed that minocycline significantly reduced OCD symptoms as an adjuvant agent to fluvoxamine in moderate-to-severe OCD patients compared to placebo. Several limitations of this study should be addressed before overgeneralizing its findings. First, the study sample size was relatively small. Second, the follow-up period was short for trials of OCD, which are usually conducted over a 12-week period, and this could partly explain the lower complete response rate (≥35% reduction in the Y-BOCS score) of this trial (31.9%) compared to a 12-week fluvoxamine trial with a response rate of 45%. A long-term follow-up period is of great importance as OCD is a chronic condition with a high chance of several relapses during the course of the disease.
Conclusion
The results of this 10-week double-blind randomized-controlled trial suggest that minocycline could be a safe and effective adjunctive treatment for more rapid and greater improvement in OCD symptoms. However, safety and efficacy of longer treatment periods with minocycline remain to be determined.
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